Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2001-09-05
2003-03-11
Cook, Rebecca (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S903000
Reexamination Certificate
active
06531493
ABSTRACT:
TECHNICAL FIELD
The invention relates to the novel use of 3-cyclopropylmethoxy4-difluoromethoxy-N-(3,5-dichloropyrid-4-yl)benzamide, a pharmacologically acceptable salt thereof or its N-oxide in the treatment of multiple sclerosis.
PRIOR ART
In the International Patent Application WO95/28926, PDE4 inhibitors—in particular rolipram—are proposed on their own or in combination with anti-inflammatory active compounds or immunomodulators for the treatment of multiple sclerosis. In the International Patent Application WO93/18770, tumor necrosis factor inhibitors—in particular pentoxyfylline—are proposed for the treatment of disorders of the central nervous system.
In the International Patent Application WO97/19686, the use of a combination of pentoxyfilline with type I interferons is described for the treatment of multiple sclerosis.
REFERENCES:
patent: 94/02465 (1994-02-01), None
patent: 95/01338 (1995-01-01), None
patent: 95/28926 (1995-11-01), None
Dinter, H., et al., “Phosphodiesterase type IV inhibitors in the treatment of multiple sclerosis”. J. Mol. Med., 75:95-102 (1997).
Genain, Claude P., et al., “Prevention of autoimmune demyelination in non-human primates by a cAMP-specific phsophodiesterase inhibitor”. Pro. Natl. Acad. Sci. USA, 92:3601-3605 (1995).
Navikas, V., et al., “The Phosphodiesterase IV Inhibitor Rolipram In Vitro Reduces the Numbers of MBP-Reactive IFN-&ggr; and TNF-&agr; MRNA Expressing Blood Mononuclear Cells in Patients with Multiple Sclerosis”. Clinical Neuropharmacology, 21:236-244 (1998).
Sommer N., et al., “Therapeutic potential of phosphodiesterase type 4 inhibition in chronic autoimmune demyelinating disease”, Journal of Neuroimmunology, 79:54-61 (1997).
Kley Hans-Peter
Sanders Karl
Altana Pharma AG
Cook Rebecca
Juneau Todd L.
Nath Gary M.
Nath & Associates PLLC
LandOfFree
3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloropyrid-... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloropyrid-..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloropyrid-... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3022362